This article has been corrected to note that Illumina's test is the third NGS-based companion diagnostic to be approved by the FDA, not the second as previously reported.
NEW YORK (GenomeWeb) – Illumina has received US Food and Drug Administration approval for a companion diagnostic test, which it has been developing with Amgen, to run on its MiSeqDx system, the company said after the close of the market on Thursday.